Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is first-line therapy in metastatic colorectal cancer, metastatic cervical cancer, HCC and also used in non-cancerous angiogenic disorders such as hereditary hemorrhagic telangiectasia. This evidence concerns the gene VEGFA and hereditary hemorrhagic telangiectasia.